[
    [
        {
            "time": "",
            "original_text": "进展最快国产疫苗！国药中生新冠疫苗在阿联酋获批上市，明年产能预计将达到超10亿剂",
            "features": {
                "keywords": [
                    "国产疫苗",
                    "国药中生",
                    "阿联酋",
                    "获批上市",
                    "产能"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "进展最快国产疫苗！国药中生新冠疫苗在阿联酋获批上市，明年产能预计将达到超10亿剂",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "辉瑞、阿斯利康纷纷下调发货量 海外新冠疫苗产量不及预期 原材料及产能成掣肘",
            "features": {
                "keywords": [
                    "辉瑞",
                    "阿斯利康",
                    "发货量",
                    "海外疫苗",
                    "产能不足"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "辉瑞、阿斯利康纷纷下调发货量 海外新冠疫苗产量不及预期 原材料及产能成掣肘",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "2021年"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "分歧加剧！北上资金连续六周加仓，公募仓位降至年内低位",
            "features": {
                "keywords": [
                    "北上资金",
                    "加仓",
                    "公募仓位",
                    "年内低位"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "分歧加剧！北上资金连续六周加仓，公募仓位降至年内低位",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【行情】疫苗股午后拉升，国药股份大涨8%，国药一致、智飞生物、复星医药等个股跟涨",
            "features": {
                "keywords": [
                    "疫苗股",
                    "拉升",
                    "国药股份",
                    "智飞生物",
                    "复星医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【行情】疫苗股午后拉升，国药股份大涨8%，国药一致、智飞生物、复星医药等个股跟涨",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "疫苗板块急速拉升，复星医药、康希诺-U、未名医药、智飞生物冲高",
            "features": {
                "keywords": [
                    "疫苗板块",
                    "拉升",
                    "复星医药",
                    "康希诺-U",
                    "未名医药",
                    "智飞生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫苗板块急速拉升，复星医药、康希诺-U、未名医药、智飞生物冲高",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
            "features": {
                "keywords": [
                    "医药",
                    "白酒",
                    "2021年度策略",
                    "次新股",
                    "圣农发展"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药生物",
                    "投资策略",
                    "2021年"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]